Drug Profile
Dopamine intranasal - Mattern Pharmaceuticals
Alternative Names: DopaMat; MPP-18Latest Information Update: 05 Mar 2023
Price :
$50
*
At a glance
- Originator Mattern Pharmaceuticals
- Class Antihypotensives; Behavioural disorder therapies; Cardiotonics; Catecholamines; Small molecules
- Mechanism of Action Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Attention-deficit hyperactivity disorder
- No development reported Parkinson's disease
Most Recent Events
- 05 Mar 2023 Dopamine intranasal - Mattern Pharmaceuticals is available for licensing as of 05 Mar 2023. https://mattern-pharma.com/
- 22 Feb 2023 Preclinical trials in Attention-deficit hyperactivity disorder is still ongoing Switzerland (Intranasal) (MetP Pharma pipeline, February 2023)
- 28 Jun 2018 No recent reports of development identified for preclinical development in Attention-deficit-hyperactivity-disorder in Switzerland (Intranasal, Gel)